SCHEMBL12336289

SCHEMBL12336289

CSc1nc(N)cc(Oc2ccc(-c3nnc(Nc4cccc(C)c4)[nH]3)cc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.56
KIT P10721 1/20 0.56
PDGFRA P16234 1/20 0.56
CDK11B P21127 1/20 0.56
FLT3 P36888 1/20 0.56
CDKL2 Q92772 1/20 0.56
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
HTT P42858 1/20 0.38
LMNA P02545 3/20 0.36
RXFP1 Q9HBX9 1/20 0.36
TSHR P16473 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CDK8 P49336 2/20 0.33
RECQL P46063 1/20 0.33
MAPT P10636 4/20 0.32
POLB P06746 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
NFKB1 P19838 1/20 0.32
ADORA2A P29274 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL627644 0.92 PDGFRB (0.50) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949269 0.91 PDGFRB (0.47) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949579 0.91 PDGFRB (0.48) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949485 0.91 PDGFRB (0.55) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949276 0.90 PDGFRB (0.48) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336482 0.90 PDGFRB (0.56) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949292 0.90 PDGFRB (0.50) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949289 0.89 PDGFRB (0.61) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949258 0.89 PDGFRB (0.43) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336424 0.88 PDGFRB (0.54) PDGFRBKITPDGFRACDK11BFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2550266-B1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTICS SOLUTIONS INC (US) 2018-05-09 EP disclosed
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 US disclosed
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130243754-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE TARGEGEN, INC. (US) 2013-09-19 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed
WO-2011119894-A2 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION KINAGEN, INC (US) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885
US-20130243754-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE AADAC, NISCH, PAICS PDGFRB 2469/4885KIT 1943/4885PDGFRA 2533/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.